Bristol-Myers Squibb: Lung Neoplasms trials

The registry lists 87 Lung Neoplasms studies with Bristol-Myers Squibb as lead sponsor. 6 are open to participants now and 34 have results posted.

Phase 1 27Phase 2 37Phase 3 19Phase 4 3No phase 13(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid MalignanciesRecruitingNCT07223047Phase 1/2
• Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)RecruitingNCT07100080Phase 2/3
• A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionRecruitingNCT07063745Phase 2/3
• A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsRecruitingNCT06618287Phase 1/2
• An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in GermanyRecruitingNCT06169956
• A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsRecruitingNCT03093116Phase 1/2
• A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)TerminatedNCT06094296Phase 2Results posted
• A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung CancerTerminatedNCT05543629Phase 1/2Results posted
• A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung CancerCompletedNCT05005273Phase 2Results posted
• Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or MutationsTerminatedNCT04161391Phase 1/2Results posted
• A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung CancerTerminatedNCT03745222Phase 3Results posted
• Study of Nivolumab for Advanced Cancers in IndiaCompletedNCT03444766Phase 4Results posted
• A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in AsiaCompletedNCT03195491Phase 3Results posted
• Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung CancerCompletedNCT03090737Phase 2Results posted
• An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03001882Phase 2Results posted
• An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced CancersCompletedNCT02869789Phase 4Results posted
• A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 WeeksCompletedNCT02713867Phase 3Results posted
• Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung CancerCompletedNCT02659059Phase 2Results posted
• Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung CancerCompletedNCT02613507Phase 3Results posted
• A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02574078Phase 1/2Results posted
• Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in METCompletedNCT02544633Phase 2Results posted
• An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based ChemotherapyCompletedNCT02538666Phase 3Results posted
• Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung CancerCompletedNCT02481830Phase 3Results posted
• An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLCCompletedNCT02409368Phase 2Results posted
• Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and CarboplatinCompletedNCT02279732Phase 3Results posted
• Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung CancerCompletedNCT02250326Phase 2Results posted
• BMS-986012 in Relapsed/Refractory SCLCCompletedNCT02247349Phase 1/2Results posted
• Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the ElderlyCompletedNCT02151149Phase 4Results posted
• A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy RegimenCompletedNCT02066636Phase 3Results posted
• An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)CompletedNCT02041533Phase 3Results posted
• Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung CancerCompletedNCT02027428Phase 3Results posted
• Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic RegimensCompletedNCT01721759Phase 2Results posted
• Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLCCompletedNCT01673867Phase 3Results posted
• Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)CompletedNCT01642004Phase 3Results posted
• Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung CancerTerminatedNCT01471197Phase 2Results posted
• Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)CompletedNCT01454102Phase 1Results posted
• Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and CarboplatinCompletedNCT01285609Phase 3Results posted
• Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung CancerCompletedNCT01165216Phase 1Results posted
• Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00540514Phase 3Results posted
• Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)CompletedNCT00527735Phase 2Results posted
• Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of ChemotherapyActive, not recruitingNCT07024862
• Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in FranceCompletedNCT06735781
• Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)Active, not recruitingNCT05853575Phase 2
• Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C MutationActive, not recruitingNCT05609578Phase 2
• Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)TerminatedNCT04975256Phase 1
• A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLCTerminatedNCT04849273Phase 1
• A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT04794010
• A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence TherapyCompletedNCT04500535
• A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyWithdrawnNCT04151563Phase 1/2
• Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in METActive, not recruitingNCT03993873Phase 1
• A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung CancerCompletedNCT03850067Phase 1
• An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual DiseaseWithdrawnNCT03770299Phase 2
• Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung CancerCompletedNCT03505515
• Treatment Patterns in Advanced Small Cell Lung Cancer (SCLC)CompletedNCT03425825
• An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung CancerWithdrawnNCT03417037Phase 3
• Observational Study for Lung Cancer Patients Treated With NivolumabCompletedNCT03382496
• A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in JapanCompletedNCT03273790
• A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung CancerWithdrawnNCT03048136Phase 3
• Study of BMS-986012 in Subjects With Small Cell Lung CanerCompletedNCT02949895Phase 1
• Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior ChemotherapyCompletedNCT02910999
• Treatment Patterns, Outcomes and Resource Use Study for Advanced Stage Non-Small Cell Lung Cancer (Squamous and Non-squamous) in the Kingdom of Saudi Arabia and United Arab EmiratesCompletedNCT02845089
• Long-term Epidemiological Follow-up of Non-small Cell Lung Cancer in ScandinaviaCompletedNCT02839629
• Trial of BMS-986012 in Combination With Platinum and EtoposideCompletedNCT02815592Phase 1
• Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung CancerTerminatedNCT02635061Phase 1
• Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic RegimenNo longer availableNCT02475382
• Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast CancerCompletedNCT02309177Phase 1
• Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCompletedNCT02223052Phase 1
• Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung CancerCompletedNCT01545947Phase 1
• Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT01024062Phase 2
• A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung CancerTerminatedNCT00975767Phase 1
• Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung CancerTerminatedNCT00850577Phase 2
• NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or LymphomaCompletedNCT00667082Phase 1
• Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00651508Phase 2
• AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line ChemotherapyCompletedNCT00547651Phase 3
• Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer TumorsTerminatedNCT00511576Phase 1
• A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)TerminatedNCT00461110Phase 1
• Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung CancerCompletedNCT00388960Phase 2
• Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior TherapyCompletedNCT00375193Phase 2
• Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)TerminatedNCT00359450Phase 2
• Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.CompletedNCT00319969Phase 2
• An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With CarboplatinCompletedNCT00274443Phase 2
• Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung CancerTerminatedNCT00179699Phase 1
• A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung CancerCompletedNCT00179686Phase 2
• Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung CancerCompletedNCT00103831Phase 1/2
• Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung CancerTerminatedNCT00099879Phase 2
• Effectiveness of KOS-862 in the Treatment of Lung CancerTerminatedNCT00080509Phase 2
• Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00073723Phase 1/2